| pubmed-article:14703897 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14703897 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:14703897 | lifeskim:mentions | umls-concept:C0149931 | lld:lifeskim |
| pubmed-article:14703897 | lifeskim:mentions | umls-concept:C0473169 | lld:lifeskim |
| pubmed-article:14703897 | lifeskim:mentions | umls-concept:C0008803 | lld:lifeskim |
| pubmed-article:14703897 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:14703897 | lifeskim:mentions | umls-concept:C0683956 | lld:lifeskim |
| pubmed-article:14703897 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:14703897 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:14703897 | pubmed:dateCreated | 2004-1-5 | lld:pubmed |
| pubmed-article:14703897 | pubmed:abstractText | The efficacy and tolerability of cinnarizine (75 mg, at bedtime) in migraine prophylaxis and the presence of possible predictive factors for therapeutic responsiveness were evaluated in an open-label pilot trial. Eighty consecutive outpatients suffering from migraine with or without aura participated in the study. After 12 weeks of therapy, 55 patients experienced a greater than 66% reduction in headache frequency and were considered responders. A significant reduction in the number of migraine days (mean reduction 58 +/- 8%) and in intake of medication to treat acute attacks (mean reduction 55 +/- 11%) was also observed. Cinnarizine was well tolerated, as documented by the low number of adverse effects. Failure to respond to previous prophylactic treatments was a negative predictive factor correlated with a poor prognosis. This study, even bearing in mind its limitations as an open-label trial, suggests that cinnarizine might be an effective prophylactic anti-migraine agent. The clinical characteristics of migraine patients do not help to predict response to treatment. | lld:pubmed |
| pubmed-article:14703897 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14703897 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14703897 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14703897 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14703897 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14703897 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14703897 | pubmed:issn | 0393-5264 | lld:pubmed |
| pubmed-article:14703897 | pubmed:author | pubmed-author:RossiPaoloP | lld:pubmed |
| pubmed-article:14703897 | pubmed:author | pubmed-author:PierelliFranc... | lld:pubmed |
| pubmed-article:14703897 | pubmed:author | pubmed-author:FiermonteGian... | lld:pubmed |
| pubmed-article:14703897 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14703897 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:14703897 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14703897 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14703897 | pubmed:pagination | 155-9 | lld:pubmed |
| pubmed-article:14703897 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:meshHeading | pubmed-meshheading:14703897... | lld:pubmed |
| pubmed-article:14703897 | pubmed:articleTitle | Cinnarizine in migraine prophylaxis: efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial. | lld:pubmed |
| pubmed-article:14703897 | pubmed:affiliation | Department of Neurology and Otolaryngology, University "La Sapienza", Rome, Italy. paolo.rossi90@tin.it | lld:pubmed |
| pubmed-article:14703897 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14703897 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14703897 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14703897 | lld:pubmed |
